Cancer biomarkers
OwnerTarek ABDEL-FATAH, Stephen CHANinventors
Life of this patent
Estimating the term…
Abstract
This invention relates to a method for determining if a cancer of a subject is expected to respond to chemotherapy.
Claims37
A method for determining if a cancer of a subject is expected to respond to chemotherapy, the method comprising:
- (i) determining if a cell in a sample of the cancer expresses granules of SPAG5 protein;
- and/or
- (ii) determining if cells in a sample of the cancer overexpresses a SPAG5 transcript;
- wherein if the sample comprises a cell that expresses granules of SPAG5 protein and/or if the sample overexpresses the SPAG5 transcript, the subject has a cancer that is expected to respond to chemotherapy;
- wherein if the sample does not comprise a cell that expresses granules of SPAG5 protein and/or if cells in the sample does not overexpress the SPAG5 transcript, the subject has a cancer that is not expected to respond to chemotherapy.
A method for determining if an ER+ cancer of a subject is expected to respond to endocrine therapy or chemotherapy, the method comprising:
- (i) determining if a cell in a sample of the ER+ cancer expresses granular SPAG5 protein;
- or
- (ii) determining if cells in a sample of the ER+ cancer overexpress a SPAG5 gene;
- wherein if the sample does not comprise a cell that expresses granular SPAG5 protein and/or if cells in the sample do not overexpress SPAG5 transcript, the subject has a cancer that is expected to respond to endocrine therapy, and
- wherein if the sample comprises a cell that expresses granular SPAG5 protein and/or if cells in the sample overexpress the SPAG5 transcript, the subject has a cancer that is expected to respond to chemotherapy.
(canceled)
(canceled)
A method according to any one of the preceding claims, wherein if the sample does not comprise a cell that expresses granules of SPAG5 protein and/or cells in the sample do not overexpress the SPAG5 transcript, the cancer is expected to be resistant to chemotherapy.
A method according to any one of the preceding claims, wherein if the sample comprises a cell that expresses granules of SPAG5 protein and/or if cells in the sample overexpress the SPAG5 transcript, the cancer is expected to be resistant to endocrine therapy.
A method according to any one of the preceding claims, wherein if the sample comprises a cell that is ER+ and comprises a cell that expresses granules of SPAG5 protein and/or if cells in the sample overexpress the SPAG5 transcript, the tumour is expected to respond to anthracycline-based combination chemotherapy and/or taxane.
A method of treating cancer in a subject with chemotherapy or endocrine therapy, the method comprising:
- (a) determining if the subject has an ER+ cancer that is expected to respond to endocrine therapy or chemotherapy, and
- (b)(i) if the ER+ cancer is expected to respond to endocrine therapy, administering a therapeutically effective amount of endocrine therapy to the subject in order to treat the cancer, or
- (b)(ii) if the ER+ cancer is expected to respond to chemotherapy, administering a therapeutically effective amount of chemotherapy to the subject in order to treat the cancer.
A method according to claim 10, wherein determining if the ER+ tumour is expected to respond to endocrine therapy comprises the method of any one of claims 3, 6 or 7.
The method according to claim 11, further comprising repeating step (a), after step (b)(i) or (b)(ii), to determine if it is appropriate for the subject to be treated with the same cancer therapy or if a different cancer therapy should be administered, optionally wherein a repetition of step (a) occurs after a relapse of the cancer.
A method of treating cancer in a subject with chemotherapy or endocrine therapy, the method comprising:
- (a) administering a therapeutically effective amount of an endocrine therapy to a subject who has a ER+ cancer, wherein the cells of the cancer do not comprise granules of SPAG5 protein and/or the cells do not overexpress SPAG5 transcript, in order to treat the cancer, or
- (b) administering a therapeutically effective amount of chemotherapy to a subject who has a ER+ cancer, wherein a cell of the cancer comprises granules of SPAG5 protein and/or the cells overexpress SPAG5 transcript, in order to treat the cancer.
A method of determining the efficacy of treating a subject suffering from cancer with a cancer therapy, the method comprising:
- (i) determining the percentage of cells that express granules of SPAG5 protein in a test sample of a cancer from a subject, and
- (ii) comparing the percentage of cells that express granules of SPAG5 protein in the test sample with a percentage of cells that express granules of SPAG5 protein in a reference sample,
- wherein if the percentage of cells that express granules of SPAG5 protein in the test sample is lower compared to the reference sample, it is indicative of the efficacy of treating the subject with the cancer therapy, and
- wherein if the percentage of cells that express granules of SPAG5 protein in the test sample is higher compared to the reference sample, it is indicative of the inefficacy of treating the subject with the cancer therapy.
A method of determining the prognosis of a subject that has a cancer, the method comprising:
- (i) determining if a cell in a sample from the cancer expresses granules of SPAG5 protein;
- and/or
- (ii) determining if cells in a sample from the cancer overexpress a SPAG5 transcript;
- wherein if the sample comprises a cell that expresses granules of SPAG5 protein and/or if cells in the sample overexpress the SPAG5 transcript, the subject has a poor prognosis.
-24. (canceled)
A method of determining if an HER2+ cancer of a subject is expected to respond to HER2 target therapy or chemotherapy, the method comprising:
- (i) determining if a cell in a sample of the HER2+ cancer expresses granular SPAG5 protein;
- or
- (ii) determining if a sample of the HER2+ cancer overexpresses a SPAG5 gene;
- wherein if the sample does not comprise a cell that expresses granular SPAG5 protein and/or if the sample does not overexpress SPAG5 transcript, the subject has a cancer that is expected to respond to HER2 target therapy, and
- wherein if the sample comprises a cell that expresses granular SPAG5 protein and/or if the sample overexpresses the SPAG5 transcript, the subject has a cancer that is expected to respond to chemotherapy.
A method of determining if an HER2+ cancer of a subject is expected to respond to HER2 target therapy, the method comprising:
- (i) determining if a cell in a sample of the HER2+ cancer expresses granular SPAG5 protein;
- or
- (ii) determining if the sample of the HER2+ cancer overexpresses a SPAG5 transcript;
- wherein if the sample does not comprise a cell that expresses granules of SPAG5 protein and/or if the sample does not overexpress the SPAG5 transcript, the subject has a cancer that is expected to respond to HER2 target therapy.
A method of determining if an HER2+ cancer of a subject is expected to respond to chemotherapy, the method comprising:
- determining if a cell in a sample of the HER2+ cancer expresses granules of SPAG5 protein, wherein if the sample comprises a cell that expresses granules of SPAG5 protein and/or if the sample overexpresses SPAG5 transcript, the subject has a cancer that is expected to respond to chemotherapy.
A method of treating cancer in a subject with chemotherapy and or HER2 target therapy, the method comprising:
- (a) determining if the subject has an HER2+ cancer that is expected to respond to HER2 target therapy or chemotherapy, and
- (b)(i) if the HER2+ cancer is expected to respond to HER2 target therapy, administering a therapeutically effective amount of HER2 target therapy to the subject in order to treat the cancer, or
- (b)(ii) if the HER2+ cancer is expected to respond to chemotherapy, administering a therapeutically effective amount of chemotherapy to the subject in order to treat the cancer.
A method of treating cancer in a subject with chemotherapy or HER2 target therapy, the method comprising:
- (a) administering a therapeutically effective amount of an HER2 target therapy to a subject who has a HER2+ cancer, wherein the cells of the cancer do not comprise granules of SPAG5 protein and/or do not overexpress SPAG5 transcript, in order to treat the cancer, or
- (b) administering a therapeutically effective amount of chemotherapy to a subject who has a HER+2 cancer, wherein a cell of the cancer comprises granules of SPAG5 protein and/or overexpress SPAG5 transcript, in order to treat the cancer.
An HER2 target therapy for use in treating an HER2+ cancer in a subject, wherein the cancer cells of the cancer do not comprise granules of SPAG5 protein or do not overexpress SPAG5 transcript.
Dependencies are inferred from the claim text.